Exploring prospects of novel drugs for tuberculosis

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 217-224

  Janssen, Saskia ^a,b   Jayachandran, Rajesh ^c   Khathi, Lulama ^d   Zinsstag, Jakob ^e   Grobusch, Martin P ^a,b,f   Pieters, Jean ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Drug targets; Drug resistance; Treatment; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AX 20017; BEDAQUILINE; BENZOTHIOPHENE DERIVATIVE; CALCINEURIN; CORONIN 1; CYCLIC GMP DEPENDENT PROTEIN KINASE; DELAMANID; GATIFLOXACIN; KHELLIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PHOSPHATASE; RIFAMYCIN DERIVATIVE; RIFAPENTIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CELL FUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; LYSOSOME; MACROPHAGE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PANDEMIC; PHAGOSOME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; MICROFILAMENT PROTEINS; SIGNAL TRANSDUCTION; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872349464     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S34006     Document Type: Article

References (69)

1. World Health Organization. Global tuberculosis control report. 2010.
2. Zinsstag J, Taleb MO, Craig PS. Health of nomadic pastoralists: new approaches towards equity effectiveness. Trop Med Int Health. 2006;11:565-568.
3. World Health Organization. M/XDR TB. Multi-drug and extensively drug-resistant tuberculosis - 2010 global report on surveillance and response. Available from: http://www.who.int/tb/features_archive/m_xdrtb_facts/en/index.html. Accessed July 12, 2012.
4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580.
5. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-1807.
6. Nunn P, Reid A, De Cock KM. Tuberculosis and HIV infection: the global setting. J Infect Dis. 2007;196 Suppl 1:S5-S14.
7. John MA, Menezes CN, Chita G, Sanne I, Grobusch MP. High tuberculosis and HIV coinfection rate, Johannesburg. Emerg Infect Dis. 2007;13:795-796.
8. Grobusch M P. Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Curr Opin Pulm Med. 2010;16:180-185.
9. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett. 1994;123:11-18.
10. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med. 2009;6:e2.
11. Jiang JR, Yen SY, Wang JY. Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients. Respirology. 2011;16:308-313.
12. Abdool Karim SS, Churchyard GJ, Abdool KQ, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009;374:921-933.
13. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-2160.
14. Bock NN, Sterling TR, Hamilton CD, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med. 2002;165:1526-1530.
15. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and effcacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387-393.
16. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50:49-55.
17. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-2166.
18. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227.
19. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-2405.
20. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54:3402-3407.
21. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15:949-954.
22. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of 8 weeks of bedaquiline (TMC207) for MDR-TB: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271-3276.
23. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol. 2005;144:80-87.
24. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofoxacin, gatifoxacin and moxifoxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10:605-612.
25. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466.
26. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofoxacin, gatifoxacin and moxifoxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128-138.
27. Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med. 1971;134:713-740.
28. Pieters J. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect. 2001;3:249-255.
29. Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol. 2001;2:569-577.
30. van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129:1287-1298.
31. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 2012;36:514-532.
32. Reece ST, Kaufmann SH. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol. 2012;15:63-70.
33. Nathan C. Role of iNOS in human host defense. Science. 2006;312: 1874-1875.
34. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004;119:753-766.
35. Huynh KK, Joshi SA, Brown EJ. A delicate dance: host response to mycobacteria. Curr Opin Immunol. 2011;23:464-472.
36. Berthet FX, Lagranderie M, Gounon P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 1998;282:759-762.
37. McKinney JD, Honer Zu BK, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406:735-738.
38. Barry CE III. New horizons in the treatment of tuberculosis. Biochem Pharmacol. 1997;54:1165-1172.
39. Chan J, Tian Y, Tanaka KE, et al. Effects of protein calorie malnutrition on tuberculosis in mice. Proc Natl Acad Sci U S A. 1996;93:14857-14861.
40. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol. 1991;3:76-82.
41. Hasan Z, Schlax C, Kuhn L, et al. Isolation and characterization of the mycobacterial phagosome: segregation from the endosomal/lysosomal pathway. Mol Microbiol. 1997;24:545-553.
42. Russell DG, Dant J, Sturgill-Koszycki S. Mycobacterium avium- and Mycobacterium tuberculosis-containing vacuoles are dynamic, fusion-competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. J Immunol. 1996;156:4764-4773.
43. Schlesinger LS. Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Curr Top Microbiol Immunol. 1996;215:71-96.
44. Berthet FX, Lagranderie M, Gounon P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 1998;282:759-762.
45. Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell. 2000;5:717-727.
46. Harth G, Horwitz MA. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of effcacy in vivo. Infect Immun. 2003;71:456-464.
47. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR Jr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol. 2003;4:949-955.
48. Honer Zu BK, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol. 1999;181:7161-7167.
49. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science. 2003;302:654-659.
50. Malik ZA, Thompson CR, Hashimi S, Porter B, Iyer SS, Kusner DJ. Cutting edge: Mycobacterium tuberculosis blocks Ca2+ signaling and phagosome maturation in human macrophages via specifc inhibition of sphingosine kinase. J Immunol. 2003;170:2811-2815.
51. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2005;102:4033-4038.
52. Scherr N, Honnappa S, Kunz G, et al. Structural basis for the specifc inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2007;104:12151-12156.
53. Walburger A, Koul A, Ferrari G, et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science. 2004;304:1800-1804.
54. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97:435-447.
55. Jayachandran R, Sundaramurthy V, Combaluzier B, et al. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell. 2007;130:37-50.
56. Nguyen L, Walburger A, Houben E, et al. Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG. J Bacteriol. 2005;187:5852-5856.
57. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409:1007-1011.
58. Av-Gay Y, Everett M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol. 2000;8: 238-244.
59. Leonard CJ, Aravind L, Koonin E V. Novel families of putative protein kinases in bacteria and archaea: evolution of the "eukaryotic" protein kinase superfamily. Genome Res. 1998;8:1038-1047.
60. Scherr N, Muller P, Perisa D, Combaluzier B, Jeno P, Pieters J. Survival of pathogenic mycobacteria in macrophages is mediated through autophosphorylation of protein kinase G. J Bacteriol. 2009;191:4546-4554.
61. Tiwari D, Singh RK, Goswami K, Verma SK, Prakash B, Nandicoori VK. Key residues in Mycobacterium tuberculosis protein kinase G play a role in regulating kinase activity and survival in the host. J Biol Chem. 2009;284:27467-27479.
62. Santhi N, Aishwarya S. Insights from the molecular docking of withanolide derivatives to the target protein PknG from Mycobacterium tuberculosis. Bioinformation. 2011;7:1-4.
63. Suzuki K, Nishihata J, Arai Y, et al. Molecular cloning of a novel actin-binding protein, p57, with a WD repeat and a leucine zipper motif. FEBS Lett. 1995;364:283-288.
64. Tailleux L, Neyrolles O, Honore-Bouakline S, et al. Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J Immunol. 2003;170:1939-1948.
65. Jayachandran R, Gatfeld J, Massner J, Albrecht I, Zanolari B, Pieters J. RNA interference in J774 macrophages reveals a role for coronin 1 in mycobacterial traffcking but not in actin-dependent processes. Mol Biol Cell. 2008;19:1241-1251.
66. Kumar D, Nath L, Kamal MA, et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell. 2010;140:731-743.
67. Seto S, Tsujimura K, Koide Y. Coronin-1a inhibits autophagosome formation around Mycobacterium tuberculosis-containing phagosomes and assists mycobacterial survival in macrophages. Cell Microbiol. 2012;14:710-727.
68. Jain A, Khanna A, Molmenti E P, Rishi N, Fung JJ. Immunosuppressive therapy. Surg Clin North Am. 1999;79:59-76.
69. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem. 2000;7: 673-692.